VIVE - Viveve Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.0780
-0.0031 (-3.82%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.0811
Open0.0881
Bid0.0000 x 900
Ask0.0000 x 1000
Day's Range0.0750 - 0.0890
52 Week Range0.0750 - 3.7100
Volume12,130,520
Avg. Volume4,872,939
Market Cap3.505M
Beta (3Y Monthly)-0.01
PE Ratio (TTM)N/A
EPS (TTM)-1.1390
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Viveve and its New CEO are Pioneering Women's Intimate Health

    ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / CEOCFO Magazine, an independent investment, healthcare, and medical news publication highlights an executive change at Viveve (VIVE) in an interview (https://www.ceocfointerviews.com/interviews/Viveve19.htm) with CEO and Director, Scott Durbin. States Mr. Durbin, "As a part of the executive leadership team, beginning as CFO in 2013, I have been integral to the company's growth strategy and commercialization efforts. Viveve is at the forefront of the booming demand for clinically proven women's intimate health and wellness treatments.

  • ACCESSWIRE

    Viveve Announces Reverse Stock Split to Regain NASDAQ Compliance

    ENGLEWOOD, CO / ACCESSWIRE / September 18, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that its Board of Directors has approved a one-for-100 reverse stock split of its common stock that is scheduled to become effective after trading closes on September 18, 2019. The company's common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on September 19, 2019. The company's common stock will continue to trade under the symbol "VIVE." At the company's Special Meeting of Stockholders held on September 16, 2019, the company's stockholders approved a proposal authorizing the company's Board of Directors to effect a reverse stock split in a range of 1:20 to 1:100 to help regain compliance with the Nasdaq minimum bid price requirement.

  • ACCESSWIRE

    Viveve to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    ENGLEWOOD, CO / ACCESSWIRE / September 17, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Ladenburg Thalmann 2019 Healthcare Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Viveve Medical Inc Earnings Call

  • ACCESSWIRE

    Viveve to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the H.C. Wainwright 21st Annual Global Investment Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau

    ENGLEWOOD, CO / ACCESSWIRE / September 3, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced an exclusive partnership agreement with Paragon Meditech Co, Ltd., a leading women’s health and medical technology distributor throughout mainland China, Hong Kong and Macau. “We are excited to partner with Paragon Meditech as we continue to expand commercial availability of the Viveve® System worldwide.

  • ACCESSWIRE

    Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions

    ENGLEWOOD, CO / ACCESSWIRE / August 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced an exclusive distribution agreement with Salient Medical Solutions, a leading distributor of innovative world-class medical devices and technologies in Canada. “We are pleased to partner with Salient Medical to expand the commercial availability of the Viveve® System to physicians and healthcare providers throughout Canada,” said Scott Durbin, chief executive officer of Viveve.

  • ACCESSWIRE

    Viveve Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    Company completed successful transition from capital sales to recurring revenue model Achieved U.S. FDA 510k and CE Mark clearances for Viveve 2.0 Expanded international distribution partnership in Middle ...

  • ACCESSWIRE

    Viveve Reports Additional Clinical Results of LIBERATE-International Trial for Stress Urinary Incontinence

    ENGLEWOOD, CO / ACCESSWIRE / August 7, 2019 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported additional clinical results from the LIBERATE-International ...

  • ACCESSWIRE

    Viveve to Host Conference Call to Provide Corporate Update and Second Quarter 2019 Results on August 8, 2019

    ENGLEWOOD, CO / ACCESSWIRE / August 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today announced that it will report its second quarter 2019 financial results after the close of the U.S. financial markets on Thursday, August 8, 2019, and will host a live conference call and webcast to provide a corporate update at 4:30 PM ET the same day. A recording of the webcast will be posted on the company’s investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve Announces Top-line Results of LIBERATE-International Trial for SUI, Q2 Transition to New U.S. Commercial Model, and Pursuit of Financial and Strategic Alternatives

    ENGLEWOOD, CO / ACCESSWIRE / July 22, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, today provided an update on the company’s clinical development programs and transition to a new U.S. business model, and also announced that it is conducting a review of financial and strategic alternatives. The company today announced that the LIBERATE-International trial, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women, did not demonstrate greater improvement in SUI in treated patients as compared with the control group, and therefore did not achieve statistical significance in the intent-to-treat-population on the primary endpoint of change from baseline to six months post-treatment in the 1-hour pad weight test.

  • ACCESSWIRE

    Viveve Announces FDA 510(k) Clearance of Viveve 2.0 Next Generation System in the U.S.

    ENGLEWOOD, CO / ACCESSWIRE / June 25, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced 510(k) K190422 clearance by the U.S. Food and Drug Administration (FDA) for the company's next-generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system for use in general surgical procedures for electrocoagulation and hemostasis. "We are pleased to have received 510(k) clearance of the Viveve 2.0 System and its consumable treatment tips from the FDA, which is another important confirmation of the safety profile of our technology.

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Viveve Medical Inc Earnings Call

  • ACCESSWIRE

    Viveve to Present at Raymond James Life Sciences and MedTech Conference

    ENGLEWOOD, CO / ACCESSWIRE / June 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Raymond James Life Sciences and MedTech Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve Reports First Quarter 2019 Financial and Operating Results

    - Successful organizational realignment resulting in decreased operating expenses - Significant progress in clinical programs targeting expanded indications in sexual function and stress urinary incontinence ...

  • ACCESSWIRE

    Viveve to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results on May 9, 2019

    ENGLEWOOD, CO / ACCESSWIRE / May 2, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2019 financial and operating results after the close of the U.S. financial markets on Thursday, May 9, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve Announces CE Mark Clearance for its Next Generation 2.0 Platform in the European Union

    ENGLEWOOD, CO / ACCESSWIRE / April 11, 2019 / Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company received CE Mark clearance for its next generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system and tips in the European Union. "As part of our ongoing regulatory strategy to expand the commercial launch of our Viveve 2.0 platform globally, we're extremely pleased that our next generation system and its consumable treatment tips are now available in over 30 countries in Europe.

  • Thomson Reuters StreetEvents

    Edited Transcript of VIVE earnings conference call or presentation 14-Mar-19 9:00pm GMT

    Q4 2018 Viveve Medical Inc Earnings Call

  • ACCESSWIRE

    Viveve Reports Fourth Quarter and Full Year 2018 Financial Results

    ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months ...

  • ACCESSWIRE

    Viveve Completes Enrollment in VIVEVE II Trial

    ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its VIVEVE II trial, a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth. "Completion of enrollment in our VIVEVE II sexual function trial represents a tremendous milestone in our Company's quest to address an enormous unmet medical need for women. An estimated 12-14 million women worldwide suffer from diminished sexual function following vaginal childbirth.

  • ACCESSWIRE

    Viveve to Host Conference Call to Discuss Fourth Quarter and Year-end 2018 Financial Results and Corporate Update on March 14, 2019

    ENGLEWOOD, CO / ACCESSWIRE / March 7, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its fourth quarter and year-end 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE

    Viveve to Present at Cowen and Company 39th Annual Health Care Conference

    ENGLEWOOD, CO / ACCESSWIRE / March 5, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Cowen and Company 39th Annual Health Care Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. The presentation will be webcast live on the Investors section of the Company's website at ir.viveve.com.

  • GlobeNewswire

    Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

    Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. The company also announced it has implemented changes to the Viveve organization to reduce operating expenses and focus on label expansion and market development for its cryogen-cooled monopolar radiofrequency (CMRF) technology.

  • GlobeNewswire

    Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

    “As we seek to achieve regulatory clearances for our CMRF technology for the treatment of SUI, a condition that affects an estimated 25-30 million women worldwide, completion of enrollment in the LIBERATE-International trial is an important milestone,” stated Scott Durbin, chief executive officer and director of Viveve. “Our single-session procedure offers women the potential for significant improvement in urine leakage and the ability to engage in their daily lives with greater comfort and control. LIBERATE-International is a multicenter, randomized, double-blinded, and sham-controlled trial with an enrollment of approximately 100 subjects at up to ten study sites in Canada.

  • GlobeNewswire

    Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency determined that the company provided sufficient data to support continued subject enrollment in the trial and that there are no safety concerns that preclude the continuation of the study.